Dendreon
Develops and manufactures personalized cellular immunotherapy for cancer patients.
Company facts
- Founded
- 1992
- Employees
- 710
- Headquarters
- United States
- CEO
- Mark D. Brouckman
- Type
- Private
- Funding
- Debt Financing · $10M · 2020
About
Dendreon is a biotechnology company focused on innovative cancer therapies. We are dedicated to the research and development of personalized treatments that empower patients with actionable options against cancer. Our flagship product, Provenge, is the first FDA-approved cancer immunotherapy for prostate cancer, and it has paved the way for further advancements in the field. At Dendreon, we continue to invest in scientific research, clinical trials, and new treatment modalities to improve patient outcomes. Our team is passionate about pushing the boundaries of science to enhance the lives of individuals battling cancer. By leveraging cutting-edge technology and a commitment to innovation, we strive to redefine the future of cancer care.
Open positions
Manager, Supplier Quality
WHO WE ARE : At Dendreon, we’re transforming the battle against cancer with personalized immunotherapy. Our flagship product, PROVENGE® (sipuleucel-T) , was the first FDA-approved immunotherapy for metastatic…
Director, Clinical Operations
WHO WE ARE : At Dendreon, we’re transforming the battle against cancer with personalized immunotherapy. Our flagship product, PROVENGE® (sipuleucel-T) , was the first FDA-approved immunotherapy for metastatic…
Vice President, Medical Affairs, Clinical Operations & Regulatory Affairs
WHO WE ARE : At Dendreon, we’re transforming the battle against cancer with personalized immunotherapy. Our flagship product, PROVENGE® (sipuleucel-T) , was the first FDA-approved immunotherapy for metastatic…
Manager, Regulatory Affairs
WHO WE ARE : At Dendreon, we’re transforming the battle against cancer with personalized immunotherapy. Our flagship product, PROVENGE® (sipuleucel-T) , was the first FDA-approved immunotherapy for metastatic…